Niva Bupa Share: Motilal Oswal 'BUY' Bole, Par Valuation Mein Gadbad? Kya Hai Sach?

INSURANCE
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Niva Bupa Share: Motilal Oswal 'BUY' Bole, Par Valuation Mein Gadbad? Kya Hai Sach?
Overview

Niva Bupa (NBH) ke shares par brokers ka view alag-alag hai. Ek taraf Motilal Oswal ne ₹92 ke target ke saath BUY rating pakdi hai, unko company ka NEP growth dikh raha hai. Lekin dusri taraf, valuation mein kaafi badi red flags aur loss ratio bhi rise ho raha hai.

Brokerage ka Bharosa vs. Market Ki Chinta

Dekho bhai, Niva Bupa (NBH) par Motilal Oswal ne ek baar phir apna BUY rating confirm kiya hai, aur target rakha hai ₹92. Unke hisab se, company ka Net Earned Premium (NEP) 3QFY26 mein 28% saal-dar-saal badh kar ₹14.5 billion ho gaya hai. Aur 9 mahine FY26 mein bhi NEP 22% badh kar ₹41 billion tak pahunch gaya hai. Brokerage ko lagta hai ki yeh growth aage bhi chalti rahegi.

Valuation Ka Bam Aur Loss Ratio Ka Pressure

Par yahan ek bada 'Lekin' hai. Itne acche NEP growth ke bawajood, NBH ki valuation metrics dekhne layak hain - negative P/E ratio aur bhayanak high EV/EBITDA multiples dikh rahe hain, jo normal bilkul nahi hai. Upper se, company ka loss ratio bhi 720 basis points badh gaya aur ab 72.3% ho gaya hai 3QFY26 mein. Operating expenses bhi 34% boom kar ₹3.2 billion ho gaye, jismein ₹200 million ka one-time labour code adjustment ka bhi impact tha.

'Strong Sell' Ki Chhap Aur Regulatory Chakkar

Sabse creepy baat ye hai ki 30 January 2026 ko ek doosre analytical platform ne valuation aur earnings ki gadbad dekh kar is stock ko 'Strong Sell' downgrade kar diya hai. Company ke auditors ne bhi IRDAI se Expense of Management limits cross karne par forbearance ke liye application ki hai FY25 ke liye, matlab regulatory level par bhi kuch chakkar chal rahe hain.

Industry Ka Future Aur NBH Ki Koshish

Waise, Indian health insurance sector future mein 15-20% CAGR se grow karega, yeh toh pakka hai. Niva Bupa ne bhi apna retail health market share 10.2% tak badhaya hai aur customer base 24.5 million lives tak pahunch gaya hai. CFO ne toh profitabilety lane ka target Q4 FY26 tak rakha hai, recently accounting changes ki wajah se losses ko blame karte hue.

Brokerage Ka Target Aur Uska Logic

Motilal Oswal ne bhi FY27/28 ke PAT estimates ko 4-13% kam kiya hai, aur claims ratio mein 150 bps increase ka andaza lagaya hai. Lekin phir bhi woh stock ko 30 times FY28 estimated IFRS PAT par value kar rahe hain, isliye unka BUY rating aur ₹92 ka target bana hua hai. Toh ek taraf Motilal Oswal bullish hai, doosri taraf reports se lag raha hai ki abhi savdhani baratni chahiye.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.